Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials

α-Defensins and outcome in patients with chronic heart failure

(2012) Heidi M. Christensen et al.   EUROPEAN JOURNAL OF HEART FAILURE

The role of monocytes and inflammation in the pathophysiology of heart failure

(2011) Benjamin J. Wrigley et al.   EUROPEAN JOURNAL OF HEART FAILURE

C-Reactive Protein

(2011) Rainer Schulz et al.   HYPERTENSION

Pitavastatin Improves Plasma Pentraxin 3 and Arterial Stiffness in Atherosclerotic Patients with Hypercholesterolemia

(2011) Hiroyuki Ohbayashi et al.   Journal of Atherosclerosis and Thrombosis

Pentraxin 3 Is a New Inflammatory Marker Correlated With Left Ventricular Diastolic Dysfunction and Heart Failure With Normal Ejection Fraction

(2011) Junichi Matsubara et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statins Enhance Formation of Phagocyte Extracellular Traps

(2010) Ohn A. Chow et al.   Cell Host & Microbe

C-reactive protein is a bystander of cardiovascular disease

(2010) S. S. Anand et al.   EUROPEAN HEART JOURNAL

Regulation of leukocyte recruitment by the long pentraxin PTX3

(2010) Livija Deban et al.   NATURE IMMUNOLOGY

Racial differences in the association of pentraxin-3 with kidney dysfunction: the Multi-Ethnic Study of Atherosclerosis

(2010) R. Dubin et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm

(2009) Barbara Bottazzi et al.   Annual Review of Immunology

Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death

(2009) Nancy Swords Jenny et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

(2009) John J.V. McMurray et al.   CIRCULATION

Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations

(2009) Kazumi Yamasaki et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

(2009) Stephane Heymans et al.   EUROPEAN JOURNAL OF HEART FAILURE

Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure

(2008) Anca Radauceanu et al.   JOURNAL OF CARDIAC FAILURE

Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review

(2008) José Paulo Araújo et al.   JOURNAL OF CARDIAC FAILURE

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET

Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure

(2007) Satoshi Suzuki et al.   AMERICAN HEART JOURNAL

Prognostic value of pentraxin 3 in patients with chronic heart failure

(2007) Norihiko Kotooka et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY